Company intelligence / Profile preview

OssDsign

Ownership: Private
Employees: ~50
Development stage: Other

Overview

OssDsign’s lead product, Catalyst®, has been cleared for market use as a synthetic bone graft in spinal fusion surgeries. It demonstrates rapid and reliable bone formation at early time points throughout the entire fusion mass. The product’s clinical data supported its clearance for interbody use based on bone graft data alone. No detailed clinical trial results are provided in the search results.

Therapeutic areas: RheumatologyNeurology
Modalities: Device (nanosynthetic bone graft)Bioceramic material-based implant
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on OssDsign.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OssDsign.

Explore the full profile